CTEV
ClaritevCNYSE / Health Care Equipment & Services
Last Price
At close
2026-07-20
Current thesis
Q1 showed continued revenue growth and solid adjusted EBITDA, while PHCS Novera gives Claritev a tangible 2026 product-rollout path. If management can keep growth moving and convert the launch into commercial wins while holding covenant compliance and improving cash flow, the equity can rerate from a depressed leverage discount.
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -13.6.
What can break
Gross debt remains high at roughly $4.6 billion, so interest burden and refinancing sensitivity still matter.
Momentum
78
Value
52
Sentiment
33
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $20.50 · Bull $31.00 · Bear $9.50
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-20 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $36.83
Why
Momentum78 · Δ7d -13.6
Value52 · Δ7d -0.2
Sentiment33 · Δ7d +0.1
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
78
26% active weight
Current posture
7d trendImproving
Δ7d
-13.6
Δ21d
-21.1
Value
52
39% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
+0.3
Sentiment
33
34% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+3.8
Why this grade
Composite grade C. Momentum 78.0 / Value 52.2 / Sentiment 33.1
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$513.48M
Beta
0.53
Shares Out
17.05M
P/E (TTM) · Derived
-1.7
P/S (TTM)
0.51
P/FCF (TTM) · Derived
-16.28
Rev YoY
+5.8%
EPS YoY
+0.6%
Gross Margin
+27.7%
Op Margin
-8.1%
Net Debt
$4.59B
Current Ratio
1.28
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology